
Colorectal Cancer: Early Screening Could Save Your Life
Colorectal cancer (CRC), including colon and rectum cancer, is the third most common cancer in the world and the third in the US as well. American Cancer Society (ACS) estimates that there are 97,220 and 43,030 new cases in 2018 for colon and rectum cancer, respectively. Different from some other types of cancers, death from CRC is 100% preventable if the disease is diagnosed at early stages.
The guideline from ACS for CRC screening suggest to start at age 50 (recently revised to 45). According to the statistics from the U.S. Centers for Disease Control and Prevention (CDC), 66.2% of the U.S. population from age 50 to 75 did CRC screening in 2014 and this number grew to 67.3% in 2016, representing increase of 3.3 million people for the testing.
CRC screening and diagnosis can be done either through stool test or visual exams of colon and rectum. A recent new stool test, ColoGuard®, approved by the FDA in 2014, is a molecular test for gene mutations and modifications (methylation). Different than the gold standard, colonoscopy, molecular diagnostic testing does not need tedious and even intimidating preparation before the test, and not to worry about possible bleeding and infection due to medical complication.
We recently developed ColoScape™ CRC mutation detection kit using our proprietary XNA technology. The feature of the detection kit:
- Is in the research use only (RUO) or CE/IVD-mark format.
- Identifies mutations commonly occurred in CRC using qPCR instruments commonly available.
- Uses liquid biopsy (blood) or Formalin-Fixed Paraffin-Embedded (FFPE) samples, rather than stool samples, which need complex DNA extraction procedure in centralized labs.
- Has a detection limit as low as 0.1% of tumor DNA among the normal cell DNA.
Watch our webinar to learn more about Coloscape™ CRC detection kit from experts. You can read this recent review on CRC, including molecular biology and genetic perspective, molecular targeted therapies and immunotherapies.
Dealing with the Respiratory Viruses that Cause Covid-19 or Flu
Influenza and COVID-19: what are they in common? Currently, the two most important respiratory viruses the healthcare authority is paying attention to are SARS-COV-2 (causing COVID-19) and influenza A and B viruses (Flu A and B). The Flu A and B viruses (named by the...
Early Cancer Detection Will Save More Lives
Cancer deaths due to failure of early detection According to the American Cancer Society researchers, it is estimated that there will be more than 600,000 people die of cancer, and 1.9 million new cancer cases in the US in 2021 alone. Seventy-one percent of the...
Assay Detects Precancerous Colorectal Cancer Lesions & Mutations
Written by Chris Wolskiat Clinical Lab Products Read the article on Clinical Lab Products
DiaCarta Positioning Liquid Biopsy Assay to Gauge Chemotherapy Response in Multiple Cancers
Written by John Gilmore at genomeweb Read the article on genomeweb Download the article NEW YORK – On the heels of newly published data, Diacarta plans to invest further in blood-based testing to determine the utility of its assays to predict drug response in patients...
KRAS Codon 12 Mutations and Detection
Next-generation sequencing (NGS) is a powerful tool that has seen a fast increase in clinical labs although only a few NGS tests have been approved by the FDA. However, there have been a lot of debate on if variants from NGS sequencing should be confirmed either by Sanger sequencing, the gold standard, or other techniques such as quantitative PCR, or the combination, or other methods.
HPV-driven Cancers and Somatic Mutations in These Cancers
Next-generation sequencing (NGS) is a powerful tool that has seen a fast increase in clinical labs although only a few NGS tests have been approved by the FDA. However, there have been a lot of debate on if variants from NGS sequencing should be confirmed either by Sanger sequencing, the gold standard, or other techniques such as quantitative PCR, or the combination, or other methods.